| Entrar

O USO DE INIBIDORES DE TIROSINA QUINASE EM PACIENTES COM LEUCEMIA MIELOIDE AGUDA

Doi: 10.47094/ICONMEGO2024/7

PALAVRAS CHAVE: FLT3 mutação; Inibidores de tirosina quinase; Leucemia Mieloide Aguda.

KEYWORDS: FLT3 mutation; Tyrosine kinase inhibitors; Acute myeloid leukemia.

ABSTRACT:
INTRODUCTION: Acute Myeloid Leukemia (AML) is a cancer of the blood and bone marrow characterized by the proliferation of immature myeloid cells, compromising the normal production of blood cells. Tyrosine Kinase Inhibitors (TKIs) block enzymes involved in cellular signals, improving therapeutic responses. The use of TKIs in AML is promising, especially in patients with mutations, such as in the FLT3 gene. However, the need for more evidence on their benefits persists. OBJECTIVE: The objective of this article is to review the literature on the impact of TKIs in the treatment of patients with AML, discussing their efficacy, mechanisms of action and adverse effects.

Autores

  • Dyulia Ferreira de Oliveira

  • Isadora Francelino Moreira

  • Mariana Maciel de Araújo

  • Muna Ahmad Omar Shahin

  • Thalita Rodrigues Corredeira Mendes

Download